Engineered immune cells take on deadly brain tumors
NCT ID NCT05241392
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a therapy made from a patient's own immune cells, engineered to target a protein called B7-H3 found on glioblastoma cells. The cells are delivered directly into the brain via a small device. The study aims to find a safe dose and check for any signs that the treatment shrinks tumors or helps patients live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B7-H3-targeting CAR-T cells
- What this could lead to
- If this works, it could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
- What could go wrong
- This is a very early, small Phase 1 trial focused on safety, so effectiveness is uncertain. Risks include serious side effects like cytokine release syndrome and neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?